Navigation Links
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
Date:12/8/2008

he AEGIS open-label clinical study, investigators examined the safety and efficacy of Soliris in Japanese patients with PNH relative to the SHEPHERD and TRIUMPH studies. The primary endpoints of the study were reduction of hemolysis and safety following 12 weeks of Soliris treatment. The AEGIS study included 29 patients at nine institutions with minimal transfusion requirements (one or more transfusion episodes in the preceding two years) and permitted enrollment of patients with significant thrombocytopenia (platelet counts greater than or equal to 30x10(9)/L). Forty-five percent of the AEGIS patients had a history of aplastic anemia or myelodysplastic syndromes. Patients were dosed in accordance with the Soliris product labels approved in the United States and European Union in 2007.

Key clinical efficacy data from the AEGIS trial presented at the ASH meeting included:

    -- Hemolysis, the primary trial endpoint, was rapidly and significantly
       reduced with Soliris treatment. A standard measure of hemolysis,
       lactate dehydrogenase (LDH), decreased 86 percent from a median of
       1,814 U/L at baseline to a median of 244 U/L following 12 weeks of
       treatment (P<0.001; normal range 103-223 U/L).
    -- Control of hemolysis resulted in an improvement in anemia as indicated
       by a reduction in packed red blood cell (PRBC) transfusion
       requirements. Transfusions were reduced 71 percent from a mean (SE) of
       5.2 (+/-1.04) PRBC units/patient during the 12-week pre-treatment
       period to 1.5 (+/-0.67) units/patient following 12 weeks of Soliris
       treatment (P<0.001 for the pre-specified median change). Transfusion
       independence was achieved in 67 percent (14/21) of patients who were
       transfusion dependent prior to treatment (P<0.001).
    -- The improvement in anemia with Soliris treatment was also indicated by
       increased hemoglobin levels. Hemoglobi
'/>"/>
SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
2. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
6. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
7. GEN Reports on the Trend Toward Predictive Toxicogenomics
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)... (NYSE: RMD ), a pioneer and innovator in ... sleep apnea solutions specifically for women, is launching a new ... night,s sleep. The Better Sleep For Women ... just part of living a busy life. It will encourage ... health, essential to not only living an active lifestyle but ...
(Date:10/1/2014)... 1, 2014  Varian Medical Systems (NYSE: ... for the fourth quarter of fiscal year 2014 following ... 2014.  The news release will be followed by a ... PT.  The news release and a link to the ... website at: www.varian.com/investor .  To access the teleconference ...
Breaking Medicine Technology:Cardinal Health 2014 Digital Report to Shareholders Now Available 2ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... 7 The 14th Annual Webby Awards named Regence BlueCross ... of Rich Media: Business to Consumer. More than a million people ... steep competition from companies that included Doritos® and NIKE. , ... The People,s Voice win ...
... May 7 Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: ... Officer, will be making a presentation at the MoneyShow Conference ... at Caesars Palace in Las Vegas .  Catalyst will ... and CPP-115. Further, the Company reported that its presentation materials ...
Cached Medicine Technology:Regence BlueCross BlueShield Wins People's Voice Award for Online Consumer Campaign in the 14th Annual Webby Awards 2Regence BlueCross BlueShield Wins People's Voice Award for Online Consumer Campaign in the 14th Annual Webby Awards 3Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference 2
(Date:10/1/2014)... (PRWEB) October 01, 2014 Join the more ... Eating Disorder Treatment Center’s first ever charity golf tournament to ... people with eating disorders who cannot afford treatment. The tournament ... Club in Eureka, Mo. , The day-long event starts ... A reception and award dinner will begin at 5 p.m. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Innovations announces ... scheduled to broadcast on Monday, October 20, 2014 at ... episode, Innovations will go behind the scenes to learn ... This segment will explore the practical help and information ... which teaches the warning signs of abuse, how to ...
(Date:10/1/2014)... Scientists at the University of Western Australia ... system proteins has the power to knock out mesothelioma ... the new study on their website. Click here ... the UWA School of Pathology and Laboratory Medicine administered ... mesothelioma with promising results. , “A timed triple ...
(Date:10/1/2014)... October 01, 2014 October is national ... and early detection plans while raising money for breast ... Breast Cancer Awareness Month in the effort to ... to promote the importance of having access to clean, ... may be linked to certain forms of cancer. ...
(Date:10/1/2014)... Two bicyclists began a journey on ... country in an effort to raise funds and awareness ... cyclists, a father-daughter team, plan to bike more than ... and finishing in Key West Florida. Funds raised ... a national nonprofit organization that assists post-9/11 service members, ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
... Treatment Model Blends Eastern and Western Therapies to Create ... ... Feb. 13 Moonview Sanctuary, the exclusive,non-residential treatment and ... approaches practiced by more than 70,experts in their fields, ...
... SUINING, China, Feb. 13 /Xinhua-PRNewswire/ -- China Health ... that Jia Minru, famous,professor of the Chinese Medicine ... be responsible for deep development,high-tech development and systematic ... The joining of Jia Minru will certainly ...
... Calif., Feb. 12 Blue Cross of California,highly values ... members have with their physicians and medical groups. It ... and up to date,both for the benefit of our ... the ways we do this is to send the ...
... Event Name ... Same Commitment to ... the Health of all Babies, CINCINNATI, ... announce that 4-year-old Bradley,Coffey of Kennedy Heights and his family will serve ... as WalkAmerica,March for Babies is the March of Dimes premier fundraising event ...
... (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and,diagnostics ... approximately,$2.3 million private financing with Montaur Capital through ... select institutional and strategic,investors of senior unsecured convertible ... principal amount of Senior Convertible,Notes to be issued ...
... 12 Edwards Lifesciences,Corporation (NYSE: EW ), the ... that it has filed a patent infringement lawsuit against,CoreValve, ... Court for,the District of Delaware. The suit seeks injunctive ... family of patents for transcatheter,heart valve technology., "Edwards ...
Cached Medicine News:Health News:High-End Treatment Center Moonview Sanctuary Unveils Four New Core Treatment Programs 2Health News:High-End Treatment Center Moonview Sanctuary Unveils Four New Core Treatment Programs 3Health News:Renowned Chinese Herbal Medicine Development Specialist Joins China Health Resources 2Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 2Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 3Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 2Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 3Health News:Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S. 2